EGFR and non-small cell lung carcinoma: It has been observed that epidermal growth factor receptor (EGFR) mutations are associated with approximately 15% of NSCLC patients, and administration of gefitinib, a selective chemotherapeutic agent targeted at EGFR, led to longer patient survival [5,6,7,8].